CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

分组1 - CytomX Therapeutics reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.17 per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $50.92 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 43.36%, compared to $41.46 million in the same quarter last year [2] - Over the last four quarters, CytomX Therapeutics has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] 分组2 - The stock has underperformed, losing about 9.9% since the beginning of the year, while the S&P 500 has declined by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $31.97 million, and for the current fiscal year, it is $0.32 on revenues of $111.42 million [7] - The Medical - Biomedical and Genetics industry, to which CytomX belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]